Search Result

Results for "

pan-PIM kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (4) DYRK (1) MDM-2/p53 (1) mTOR (1) Pim (14) Reference Standards (1) STAT (1)
By Research Areas:	Cancer (14)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18095

CX-6258 3 Publications Verification	Pim	Cancer
CX-6258 is a potent and kinase selective **pan-Pim kinases inhibitor, with IC₅₀**s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-19322B

PIM-447 dihydrochloride Maximum Cited Publications 8 Publications Verification LGH447 dihydrochloride	Pim Apoptosis	Cancer
PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-PIM kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects. PIM447 dihydrochloride induces apoptosis .

HY-16976

GDC-0339 2 Publications Verification	Pim	Cancer
GDC-0339 is a potent, orally bioavailable and well tolerated **pan-Pim kinase inhibitor, with K_i**s of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma .

HY-19322

PIM447 Maximum Cited Publications 8 Publications Verification LGH447	Pim Apoptosis	Cancer
PIM447 (LGH447) is a potent, orally available, and selective pan-PIM *kinase* inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces apoptosis .

HY-18095A

CX-6258 hydrochloride hydrate 3 Publications Verification	Pim	Cancer
CX-6258 hydrochloride hydrate is a potent and kinase selective **pan-Pim kinases inhibitor, with IC₅₀**s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-101870

Uzansertib INCB053914	Pim	Cancer
Uzansertib (INCB053914) is an orally active, ATP-competitive pan-PIM *kinase* inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-101870B

Uzansertib phosphate INCB053914 phosphate	Pim	Cancer
Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM *kinase* inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-18095B

CX-6258 hydrochloride 3 Publications Verification	Pim	Cancer
CX-6258 hydrochloride is a potent and kinase selective **pan-Pim kinases inhibitor, with IC₅₀**s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively .

HY-101783

GNE-955	Pim	Cancer
GNE-955 is a potent and orally active pan Pim *kinase* inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.

HY-142656

PIM-IN-1	Pim	Cancer
PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, EC₅₀ = 61 nM; pS6, EC₅₀ = 71 nM).

HY-101870BR

Uzansertib phosphate (Standard) INCB053914 phosphate (Standard)	Reference Standards Pim	Cancer
Uzansertib phosphate (Standard) is the analytical standard of Uzansertib phosphate (HY-101870B). This product is intended for research and analytical applications. Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-PIM kinase inhibitor with IC₅₀s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines .

HY-181925

FD2024	Apoptosis Pim mTOR	Cancer
FD2024 is a pan-PIM kinase inhibitor with IC₅₀ values of 0.17 nM, 1.86 nM, and 0.38 nM against PIM-1, PIM-2, and PIM-3, respectively. FD2024 induces cell apoptosis. FD2024 inhibits the phosphorylation of mTOR, p70S6K, S6, 4EBP1, and BAD proteins. FD2024 exhibits anti-acute myeloid leukemia activity. FD2024 can be used in studies related to acute myeloid leukemia .

HY-122670

VS-II-173	Pim Apoptosis AMPK DYRK STAT MDM-2/p53	Cancer
VS-II-173 is a **pan-Pim kinase inhibitor with IC₅₀ values of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2** at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPK_α1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC₅₀ > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations .

HY-183198

PIM-IN-5	Pim	Cancer
PIM-IN-5 is a PIM kinase inhibitor. PIM-IN-5 can be used for the research of acute myeloid leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

pan-PIM kinase

Inhibitors & Agonists